Greater state bank04.03.2019
Greater state bank most advanced product candidate has completed pivotal clinical studies and an application for market authorization has been submitted to the US FDA earlier this year. All of LifeCycle Pharmas product candidates are based on the companys MeltDose technology, which is particularly suited to create new and improved versions of existing drugs. By applying the MeltDose technology to improve the efficacy of well-known greater state bank valuable drugs, we believe that we are able to develop products significantly faster and cheaper and with a higher success rate compared to the development of completely new drugs.
We believe, that the Breater technology may not only improves the efficacy of drugs. By enhancing the absorption of drugs in the body, we believe that the technology may also be used to reduce the side effects associated with such medication.
LifeCycle Pharma is listed on the OMX Nordic Exchange (LCP) and a member of the MidCap index. The company has a late-stage product pipeline with a portfolio of six proprietary product candidates in clinical development.